The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hung, C.-F.
Right arrow Articles by Wu, T.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hung, C.-F.
Right arrow Articles by Wu, T.-C.
The Journal of Immunology, 2001, 166: 5733-5740.
Copyright © 2001 by The American Association of Immunologists

Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen1

Chien-Fu Hung2,*, Wen-Fang Cheng2,*, Chee-Yin Chai*, Keng-Fu Hsu*, Liangmei He*, Morris Ling* and T.-C. Wu3,*,{dagger},{ddagger},§

Departments of * Pathology, {dagger} Obstetrics and Gynecology, {ddagger} Molecular Microbiology and Immunology, and § Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21205; and Department of Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan

The potency of naked DNA vaccines is limited by their inability to amplify and spread in vivo. VP22, a HSV-1 protein, has demonstrated the remarkable property of intercellular transport and may thus provide a unique approach for enhancing vaccine potency. Therefore, we created a novel fusion of VP22 with a model Ag, human papillomavirus type 16 E7, in a DNA vaccine that generated enhanced spreading and MHC class I presentation of Ag. These properties led to a dramatic increase in the number of E7-specific CD8+ T cell precursors in vaccinated mice (around 50-fold) and converted a less effective DNA vaccine into one with significant potency against E7-expressing tumors. In comparison, nonspreading VP221–267 mutants failed to enhance vaccine potency. Our data indicated that the potency of DNA vaccines may be dramatically improved through intercellular spreading and enhanced MHC class I presentation of Ag.




This article has been cited by other articles:


Home page
J. Immunol.Home page
M.-A. Perales, A. Diab, A. D. Cohen, D. W. Huggins, J. A. Guevara-Patino, V. M. Hubbard, M. E. Engelhorn, A. A. Kochman, J. M. Eng, F. Mortazavi, et al.
DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation
J. Immunol., September 15, 2006; 177(6): 4159 - 4167.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-W. Liao, C.-A. Chen, C.-N. Lee, Y.-N. Su, M.-C. Chang, M.-H. Syu, C.-Y. Hsieh, and W.-F. Cheng
Fusion Protein Vaccine by Domains of Bacterial Exotoxin Linked with a Tumor Antigen Generates Potent Immunologic Responses and Antitumor Effects
Cancer Res., October 1, 2005; 65(19): 9089 - 9098.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
W. Mwangi, W. C. Brown, G. A. Splitter, Y. Zhuang, K. Kegerreis, and G. H. Palmer
Enhancement of antigen acquisition by dendritic cells and MHC class II-restricted epitope presentation to CD4+ T cells using VP22 DNA vaccine vectors that promote intercellular spreading following initial transfection
J. Leukoc. Biol., August 1, 2005; 78(2): 401 - 411.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. Zheng, L. A. Babiuk, and S. van Drunen Littel-van den Hurk
Bovine Herpesvirus 1 VP22 Enhances the Efficacy of a DNA Vaccine in Cattle
J. Virol., February 1, 2005; 79(3): 1948 - 1953.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Garg, A. E. Oran, H. Hon, and J. Jacob
The Hybrid Cytomegalovirus Enhancer/Chicken {beta}-Actin Promoter along with Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances the Protective Efficacy of DNA Vaccines
J. Immunol., July 1, 2004; 173(1): 550 - 558.
[Abstract] [Full Text] [PDF]


Home page
CROBMHome page
K. Devaraj, M. L. Gillison, and T.-C. Wu
DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Critical Reviews in Oral Biology & Medicine, September 1, 2003; 14(5): 345 - 362.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C.-F. Hung, W.-F. Cheng, L. He, M. Ling, J. Juang, C.-T. Lin, and T-C. Wu
Enhancing Major Histocompatibility Complex Class I Antigen Presentation by Targeting Antigen to Centrosomes
Cancer Res., May 15, 2003; 63(10): 2393 - 2398.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C.-F. Hung, L. He, J. Juang, T.-J. Lin, M. Ling, and T.-C. Wu
Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen
J. Virol., February 22, 2002; 76(6): 2676 - 2682.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.